StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, FY2025
978
Period ended Dec 31, 2025
Change on a year earlier
+24.6%
785 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025978+24.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
FY2024Dec 31, 2024785+29.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023605+41.4%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022428+15.7%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 2021370+31.7%Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
FY2020Dec 31, 2020281+70.3%Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 2019165+129.2%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2018Dec 31, 201872–Form 10-K (filed 2021-02-25) ↗

Breakdown

What makes up prevymis (letermovir — cmv prophylaxis) — worldwide sales ($m)

Cite this data

StockData. (2026). Merck Prevymis (letermovir — CMV prophylaxis) — Worldwide sales ($M) ($M), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_prevymis

See every metric in the Merck KPI table. Data updated Oct 26, 2026.